Evidence map›Paper›PMID 33236509›Full record

Trial reportDiabetes, obesity & metabolism2021

Results from the Effects of MEtformin on cardiovasculaR function in AdoLescents with type 1 Diabetes (EMERALD) study: A brief report of kidney and inflammatory outcomes.

Kalie L Tommerdahl, Petter Bjornstad, Jessica Kendrick, Melanie Cree-Green, Amy D Baumgartner, Laura Pyle, Jane E B Reusch, Kristen J Nadeau

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kalie L TommerdahlDepartment of Pediatrics, Section of Pediatric Endocrinology, Children's Hospital Colorado and University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0003-1132-1574
Petter BjornstadDepartment of Pediatrics, Section of Pediatric Endocrinology, Children's Hospital Colorado and University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0002-5160-2947
Jessica KendrickDepartment of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Melanie Cree-GreenDepartment of Pediatrics, Section of Pediatric Endocrinology, Children's Hospital Colorado and University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0003-1593-1695
Amy D BaumgartnerDepartment of Pediatrics, Section of Pediatric Endocrinology, Children's Hospital Colorado and University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Laura PyleDepartment of Pediatrics, Section of Pediatric Endocrinology, Children's Hospital Colorado and University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Jane E B ReuschCenter for Women's Health Research, Division of General Internal Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
Kristen J NadeauDepartment of Pediatrics, Section of Pediatric Endocrinology, Children's Hospital Colorado and University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0002-0477-3356
Colorado School of Public Health · USChildren's Hospital Colorado · USUniversity of Colorado Anschutz Medical Campus · US

Funding

NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Paul S. Maclean · 1995 to 2026
$32.6M
University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LORI SUSSEL · 2020 to 2026
$10.8M
TRAINING IN RENAL &ELECTROLYTE DISEASE &HYPERTENSIONT32DK007135 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI JOHNSON, RICHARD JOSEPH, KENDRICK, JESSICA B · 1986 to 2024
$5.3M
Training Program in Diabetes ResearchT32DK063687 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Andrea Steck · 2002 to 2026
$5.2M
Bicarbonate Administration In CKDR01HL132868 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI KENDRICK, JESSICA B · 2017 to 2020
$1.7M
Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes StudyK23DK116720 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI BJORNSTAD, PETTER · 2018 to 2022
$963k
Influence of peripheral insulin resistance and hepatic lipogenesis on liver fat in obese PCOS girlsK23DK107871 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI CREE, MELANIE G · 2015 to 2018
$743k
Colorado Clinical and Translational Science Institute (TL1)TL1RR025778 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$730k
The Next Generation of Innovative Cardiovascular Clinical/Translational ResearchersK24HL145076 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI NADEAU, KRISTEN JANE · 2019 to 2023
$574k
Targeting Microvascular Contributors to Impaired Functional Exercise Capacity in DiabetesI01BX002046 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI REUSCH, JANE E · 2014 to 2024
–
Cardiovascular Mechanisms of Exercise Intolerance in Diabetes and the Role of SexI01CX001532 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI REUSCH, JANE E · 2017 to 2022
–
BLRD VA I01 BX002046CSRD VA I01 CX001532NCATS NIH HHS UL1 TR002535NCRR NIH HHS TL1 RR025778NHLBI NIH HHS K24 HL145076NHLBI NIH HHS R01 HL132868NIDDK NIH HHS K23 DK107871NIDDK NIH HHS K23 DK116720NIDDK NIH HHS P30 DK048520NIDDK NIH HHS P30 DK116073NIDDK NIH HHS T32 DK007135NIDDK NIH HHS T32 DK063687
6 · The paper itself

Abstract

Youth with type 1 diabetes (T1D) demonstrate insulin resistance, independently of glycaemia, when compared to normoglycaemic peers. Insulin resistance increases the risk of cardiovascular disease and diabetic kidney disease, factors also associated with systemic inflammation. We evaluated the effect of metformin on markers of inflammation and diabetic kidney disease in adolescents with T1D. EMERALD, a double-blind, randomized, placebo-controlled trial of 3 months of metformin in 48 participants aged 12-21 years with T1D, included baseline and follow-up assessments of serum creatinine and cystatin C to estimate glomerular filtration rate (eGFR), aspartate aminotransferase, alanine aminotransferase, high-sensitivity C-reactive protein, white blood count, platelets, adiponectin, leptin, and urine albumin: creatinine ratio (UACR). Metformin was associated with a 13.9 mL/min/1.73 m

Indexed as

Diabetes Mellitus, Type 1Diabetic NephropathiesMetforminAdolescentAlbuminuriaCreatinineGlomerular Filtration RateHumansKidneyCreatinineMetforminalbuminuriadiabetic kidney diseaseglomerular filtration rateinflammatory markerstype 1 diabetes

Identifiers

PMID33236509
PMCPMC8007280
OpenAlexW3109775670

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.